TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26928413

Group type: EXPERIMENTAL
Intervention: Parent-reported medical errors
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Parent-reported preventable adverse events (AEs)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Demographic and clinical data analysis
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Medical record review
Number of subjects: 471
Study: 25177814

Group type: EXPERIMENTAL
Intervention: Meldonium (500 mg/day) for 3 months
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no meldonium)
Number of subjects: 56
Study: 21823980

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (PUS) 1 MHz, 1:9 ratio, 0.5 W/cm2 for maxillary sinuses, 1 W/cm2 for frontal sinuses, 10 sessions, 3 days per week, every other day.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous ultrasound (CUS) 1 MHz, 1:9 ratio, 0.5 W/cm2 for maxillary sinuses, 1 W/cm2 for frontal sinuses, 10 sessions, 3 days per week, every other day.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound (PUS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous ultrasound (CUS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 20350924

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 389

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Insulin glargine and Pioglitazone
Number of subjects: 389
Study: 18597891

Group type: EXPERIMENTAL
Intervention: Active-search condition with large amount of information
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Read-only condition with medium amount of information
Number of subjects: 120

Group type: COMPARATOR
Intervention: Read-only condition with large amount of information
Number of subjects: 120
Study: 16162049

Group type: EXPERIMENTAL
Intervention: Positive affect linked to behavioral goals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral or negative affect linked to behavioral goals
Number of subjects: 0
Study: 12660281

Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 166

Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 166
Study: 10366369

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins
Number of subjects: 11
Study: 7483804

Group type: EXPERIMENTAL
Intervention: Meningococcal group B (15:P1.3) outer membrane protein vaccine, two doses six weeks apart
Number of subjects: 40811

Group type: EXPERIMENTAL
Intervention: Meningococcal group B (15:P1.3) outer membrane protein vaccine
Number of subjects: 40811

Group type: COMPARATOR
Intervention: Control vaccine (Menomune, A, C, Y and W135 meningococcal polysaccharide vaccine)
Number of subjects: 40811
Study: 2278224

Group type: EXPERIMENTAL
Intervention: Oral indomethacin (0.2 mg/kg at 24th, 36th, and 60th hour of age)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (1 ml 0.33% saline in 5% G/W solution at the same schedule)
Number of subjects: 32
Study: 7400476

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Terbutaline
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 29723441

Group type: EXPERIMENTAL
Intervention: Hydrocodone extended-release (ER) 45 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intranasal administration of finely milled hydrocodone ER, hydrocodone powder, and finely milled Zohydro® ER
Number of subjects: 2
Study: 29193014

Group type: EXPERIMENTAL
Intervention: Counseling intervention to correct student misperceptions of the profitability of higher education.
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 9000

Group type: EXPERIMENTAL
Intervention: Counseling intervention.
Number of subjects: 9000
Study: 26553376

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive-pressure ventilation (NIPPV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 200
Study: 25568560

Group type: EXPERIMENTAL
Intervention: Capsules containing 500 mg of powdered sumac fruits, three times a day for one month
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 72
Study: 22677302

Group type: EXPERIMENTAL
Intervention: 75 mg/ml diclofenac sodium HPβCD (i.m.)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 75 mg/ml diclofenac sodium HPβCD (s.c.)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 25, 50, or 75 mg/ml diclofenac sodium HPβCD (s.c.)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Voltaren® 75 mg/3 ml (i.m.)
Number of subjects: 42
Study: 20194850

Group type: EXPERIMENTAL
Intervention: Cap 45 (radiotherapy 45 Gy/25 fractions with concurrent capecitabine 800 mg/m² twice daily 5 days per week)
Number of subjects: 598

Group type: COMPARATOR
Intervention: Capox 50 (radiotherapy 50 Gy/25 fractions with capecitabine 800 mg/m² twice daily 5 days per week and oxaliplatin 50 mg/m² once weekly)
Number of subjects: 598
Study: 18071094

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Individual counseling
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Antidepressants plus counseling
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 314

Group type: COMPARATOR
Intervention: Treatment offered
Number of subjects: 314
Study: 15900097

Group type: EXPERIMENTAL
Intervention: Low-dose FK506
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no FK506)
Number of subjects: 34
Study: 11988250

Group type: EXPERIMENTAL
Intervention: Ibuprofen prophylaxis for patent ductus arteriosus
Number of subjects: 0
Study: 9457018

Group type: EXPERIMENTAL
Intervention: Bionator
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Headgear/Biteplane
Number of subjects: 249

Group type: COMPARATOR
Intervention: Control
Number of subjects: 249
Study: 7608428

Group type: EXPERIMENTAL
Intervention: Zatebradine (5 mg twice a day)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 1700580

Group type: EXPERIMENTAL
Intervention: Dimethylsulfoxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pentosampolysulphate
Number of subjects: 0
Study: 342622

Group type: EXPERIMENTAL
Intervention: Monovalent whole‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Monovalent split‐virus vaccine (200, 400, and 800 chick cell‐agglutinating units per dose)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Whole‐virus vaccine
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 208
Study: 6459776

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.125 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.25 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide 0.5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Salbutamol 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study: 31500629

Group type: EXPERIMENTAL
Intervention: Combination containing the probiotic Bifidobacterium longum BB536 and red yeast rice extract
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30227910

Group type: EXPERIMENTAL
Intervention: LARC initiation within 90 days after abortion in KPNC facilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: LARC initiation within 90 days after abortion in contracted facilities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-acting or no contraception initiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No contraception initiation
Number of subjects: 0
Study: 26969812

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0
Study: 25163995

Group type: EXPERIMENTAL
Intervention: Musical Concentration Training with Pepe (MusiKo mit Pepe)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 22343090

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Antidepressants (escitalopram or amitriptyline)
Number of subjects: 400
Study: 20120421

Group type: EXPERIMENTAL
Intervention: Vivité Skin Care System
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cetaphil moisturizing regimen
Number of subjects: 36
Study: 17324679

Group type: EXPERIMENTAL
Intervention: Mindfulness training (six 1-hour sessions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Guided Visual Imagery (two 1-hour sessions)
Number of subjects: 42
Study: 16003622

Group type: EXPERIMENTAL
Intervention: Handpiece usage during surgical exodontia procedures
Number of subjects: 100

Group type: COMPARATOR
Intervention: Manufacturers' recommendations for handpiece use time cycles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Operator experience
Number of subjects: 100
Study: 12143093

Group type: EXPERIMENTAL
Intervention: Placement of a separator
Number of subjects: 142

Group type: COMPARATOR
Intervention: Upper alginate impression
Number of subjects: 142

Group type: COMPARATOR
Intervention: Separator placement
Number of subjects: 142

Group type: COMPARATOR
Intervention: Band placement
Number of subjects: 142

Group type: COMPARATOR
Intervention: Archwire adjustment
Number of subjects: 142
Study: 10421307

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 0
Study: 7796781

Group type: EXPERIMENTAL
Intervention: AcOH (olive oil plus 1 g acetic acid in the form of vinegar)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: AcOH + Bread (olive oil plus 1 g acetic acid in the form of vinegar followed by 50 g carbohydrate portions of white bread)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: AcNa (olive oil plus sodium acetate in the form of vinegar neutralized to pH 6.0)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Blank + Bread (olive oil without vinegar followed by 50 g carbohydrate portions of white bread)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: AcNa + Bread (olive oil plus sodium acetate followed by 50 g carbohydrate portions of white bread)
Number of subjects: 5
Study: 2368891

Group type: EXPERIMENTAL
Intervention: Chloral hydrate 40 mg/kg (Group 1)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg/kg (Group 2)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.005 mg/kg (both groups)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg (both groups)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Placebo (both groups)
Number of subjects: 339
Study: 97705

Group type: EXPERIMENTAL
Intervention: Enthusiastic messages of drug effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dental staff perceived as friendly and supportive
Number of subjects: 0
Study: 29336900

Group type: EXPERIMENTAL
Intervention: Low-dose 99mTc-MIBI + NC (group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose 99mTc-MIBI (group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 27008092

Group type: EXPERIMENTAL
Intervention: Global medium
Number of subjects: 73

Group type: COMPARATOR
Intervention: Single Step Medium (SSM)
Number of subjects: 73
Study: 24356394

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Darbepoetin α
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study: 23517248

Group type: EXPERIMENTAL
Intervention: CAIRO trial patients
Number of subjects: 1946

Group type: COMPARATOR
Intervention: Non-eligible non-trial patients
Number of subjects: 1946
Study: 20101012

Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training (n = 54)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (n = 52)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Twice-weekly balance and tone training (control group, n = 49)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both resistance training groups
Number of subjects: 155
Study: 17762913

Group type: EXPERIMENTAL
Intervention: rimexolone 1% one eye drop every 4 h (n = 44 eyes)
Number of subjects: 80

Group type: COMPARATOR
Intervention: prednisolone acetate 1% one eye drop every 4 h (n = 36 eyes)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rimexolone 1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: prednisolone acetate 1%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: rimexolone 1% and prednisolone acetate 1%
Number of subjects: 80
Study: 16873556

Group type: EXPERIMENTAL
Intervention: DFA analysis in nondiabetic subjects; DFA exponent alpha = 1.25 +/- 0.29
Number of subjects: 27

Group type: COMPARATOR
Intervention: DFA analysis in diabetic patients; DFA exponent alpha = 1.65 +/- 0.30
Number of subjects: 27
Study: 12828584

Group type: EXPERIMENTAL
Intervention: Aminophylline treatment in group C (n=5)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Group B (n=8)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Group C (n=5)
Number of subjects: 25
Study: 10731502

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg/d for 28 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lactation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 9180204

Group type: EXPERIMENTAL
Intervention: Atovaquone plus proguanil
Number of subjects: 154

Group type: COMPARATOR
Intervention: Quinine plus tetracycline
Number of subjects: 154
Study: 7506169

Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg orally, twice daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Piroxicam (20mg orally, once daily)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100mg orally, twice daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 3775328

Group type: COMPARATOR
Intervention: Load of 0 kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Load of 10 kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Load of 15 kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Load of 20 kg
Number of subjects: 9
Study: 31647379

Group type: EXPERIMENTAL
Intervention: Redundant condition (both visual and verbal instructions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual condition (instructions shown using arrow symbols)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal condition (instructions given orally)
Number of subjects: 0
Study: 29562258

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Low Glasgow coma scale
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: High blood urea-nitrogen
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Acidotic base-excess
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Development of shock
Number of subjects: 1217

Group type: EXPERIMENTAL
Intervention: Development of coma
Number of subjects: 1217
Study: 27233673

Group type: EXPERIMENTAL
Intervention: Preoperative warm-up in a VRSS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no warm-up)
Number of subjects: 20
Study: 24238032

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DXM) 0.2 mg·kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Promethazine 0.5 mg·kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mivacurium
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 80
Study: 22023655

Group type: EXPERIMENTAL
Intervention: Mite allergen-impermeable mattress covers
Number of subjects: 1282

Group type: COMPARATOR
Intervention: Placebo mattress covers
Number of subjects: 1282
Study: 20007307

Group type: EXPERIMENTAL
Intervention: Low sodium diet (58 mmol . L(‐1) . d(‐1))
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High sodium diet (170 mmol . L(‐1) . d(‐1))
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentrations after upright posture
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Plasma aldosterone concentrations when supine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Urinary aldosterone excretion rates
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Week 3 measurements (blood pressure, body weight, urinary volume, creatinine, serum sodium and potassium)
Number of subjects: 58
Study: 18797348

Group type: EXPERIMENTAL
Intervention: Met allele carriers
Number of subjects: 96

Group type: COMPARATOR
Intervention: Val/Val homozygotes
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Patients with left and bilateral infarctions
Number of subjects: 96
Study: 15699222

Group type: EXPERIMENTAL
Intervention: Increasing targeted sedentary behaviors by 25‐50%
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Decreasing targeted sedentary behaviors by 25‐50%
Number of subjects: 16
Study: 14644671

Group type: EXPERIMENTAL
Intervention: Intensive peer education sessions (20 bi-weekly sessions over 1 year and quarterly booster sessions for 2 years)
Number of subjects: 594

Group type: COMPARATOR
Intervention: Control group (received brochures on basic lead prevention strategies)
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Intensive peer education
Number of subjects: 594
Study: 10820694

Group type: EXPERIMENTAL
Intervention: Communication interventions (three styles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxing music
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational videos
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recreational activities
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interacting with patients with caring and concern
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study: 8899083

Group type: EXPERIMENTAL
Intervention: famotidine 10 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ranitidine 75 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 1508355

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine-fentanyl preheated to 37 degrees C (n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.5% bupivacaine-fentanyl at room temperature (20 degrees C) (n = 25)
Number of subjects: 50
Study: 6828237

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 210

Group type: COMPARATOR
Intervention: metrizoate
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Both iohexol and metrizoate
Number of subjects: 210
Study: 31330149

Group type: EXPERIMENTAL
Intervention: 50g sucrose
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 50g sucrose with 160mg of vitamin C
Number of subjects: 13

Group type: COMPARATOR
Intervention: 300ml water (control)
Number of subjects: 13
Study: 30145934

Group type: EXPERIMENTAL
Intervention: Coronary CT Angiography (CTA) plus standard care
Number of subjects: 4146

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 4146
Study: 26789727

Group type: EXPERIMENTAL
Intervention: NPM1-mutated transcripts present after second chemotherapy cycle
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Minimal residual disease status determined by NPM1-mutated transcripts
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Sequential monitoring of minimal residual disease
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Detection of NPM1 mutations at relapse
Number of subjects: 346
Study: 24678999

Group type: EXPERIMENTAL
Intervention: Cardiac-resynchronization therapy with a defibrillator (CRT-D)
Number of subjects: 1691

Group type: COMPARATOR
Intervention: Defibrillator therapy alone
Number of subjects: 1691

Group type: EXPERIMENTAL
Intervention: Patients without left bundle-branch block
Number of subjects: 1691
Study: 22913215

Group type: EXPERIMENTAL
Intervention: 9 g of L-arginine for 3 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (20 healthy lean subjects)
Number of subjects: 60
Study: 20948193

Group type: EXPERIMENTAL
Intervention: Low-fat high simple carbohydrate diet (SCHO)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low-fat high complex carbohydrate diet (CCHO)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 47
Study: 17878469

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bronchodilators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagnostic procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical parameters
Number of subjects: 0
Study: 15792748

Group type: EXPERIMENTAL
Intervention: Preemptive thoracic epidural (TE) analgesia
Number of subjects: 56

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 56
Study: 12148095

Group type: EXPERIMENTAL
Intervention: Intravenous CT angiography (CTA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intraarterial digital subtraction angiography (DSA)
Number of subjects: 80
Study: 10532976

Group type: EXPERIMENTAL
Intervention: Hybrid laser treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 45
Study: 8593974

Group type: EXPERIMENTAL
Intervention: Triflusal 300 mg twice daily
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 1592254

Group type: EXPERIMENTAL
Intervention: Psychiatric consultation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 2869616

Group type: EXPERIMENTAL
Intervention: Oxprenolol slow release 160 mg b.i.d.
Number of subjects: 1741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1741
Study: 30800121

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (100,000 IU every 15 days for 3 months)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38